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Abstract
We hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-
deficit/hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults
performed the Multi-Source Interference Task (MSIT) during fMRI at baseline and after 6 weeks
of ATMX treatment. ATMX was associated with increased fMRI activation of dorsolateral
prefrontal cortex, parietal cortex and cerebellum; but not dorsal anterior midcingulate cortex
(daMCC). These results suggest that ATMX and MPH have similar but non-identical brain effects.
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1. Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is among the most common
neurobehavioral disorders in children and adolescents, and frequently persists into
adulthood. Atomoxetine (ATMX), a non-stimulant norepinephrine transporter (NET)
specific reuptake inhibitor, is a safe and effective treatment for ADHD (Adler et al., 2005).
While a few studies have provided insights (Arnsten, 2006; Seneca et al., 2006; Logan et al.,
2007; Pliszka, 2007; Chamberlain et al., 2009; Takano et al., 2009), the neural mechanisms
by which ATMX exerts therapeutic effects remain unresolved.
Convergent data implicate dysfunction of many brain regions in ADHD pathophysiology,
including the dorsal anterior midcingulate (daMCC), dorsolateral prefrontal (DLPFC), and
parietal cortices (together, the cingulo-frontal-parietal [CFP] cognitive-attention network),
along with striatum and cerebellum (Paloyelis et al., 2007; Bush, 2009; Bush, 2011). Thus, it
was expected that ATMX treatment would affect the CFP network. We used the Multi-
Source Interference Task (MSIT), a cognitive fMRI paradigm with demonstrated ability to
activate daMCC and the CFP network (Bush and Shin, 2006). Since clinical response may
not maximally differentiate from placebo until 6 weeks with ATMX (Montoya et al., 2009)
or MPH (Spencer et al., 2005; Biederman et al., 2006), we scanned subjects at baseline and
after 6 weeks treatment.
Specifically, we hypothesized ATMX would increase fMRI activation in CFP regions that
subserve attention and cognition. We also predicted that compared to our previously
published sample of 21 adults with ADHD-childhood onset (ADHD-CO) (Bush et al., 2008)
ATMX fMRI responses would be similar to those produced by MPH and differentiable from
placebo. To facilitate cross-study comparability and explore the degree of neurobiological
overlap of ADHD-NOS with ADHD-CO, we compared baseline MSIT fMRI data of the 11
adults with ADHD-NOS to that from the previously published sample.
2. Methods
Methods were identical to those used in the previously published sample (Bush et al., 2008),
except as indicated here, and are included in the Supplemental Material. Written informed
consent was obtained per Massachusetts General Hospital Subcommittee on Human
Subjects guidelines. Eleven unmedicated adults (6M/5F) with ADHD, Not Otherwise
Specified (ADHD-NOS) completed the study. The previously published MPH (N = 11) and
placebo (N = 10) samples (Bush et al., 2008) were diagnosed with ADHD-childhood onset
(ADHD-CO). Inclusion and exclusion criteria for all subjects (N = 32) were otherwise
identical. MSIT procedures (Bush and Shin, 2006; Bush et al., 2008) are summarized in
Supplemental Figure 1. The ATMX group displayed the expected performance effects and
did not differ in severity or demographically from the prior published sample (see
Supplemental, Table 1).
Functional MRI analyses were as follows. The primary contrast examined which brain
regions displayed an effect of 6 weeks of ATMX. A multi-step random effects repeated
measures ANOVA GLM analysis was used. First, a mask representing all voxels
MSITInterference > MSITControl (P < .05 uncorrected) for all 32 subjects (11 ATMX, 11
MPH, 10 placebo) during Scan 2 was applied to restrict analysis to brain areas specifically
involved in cognition. Within masked voxels for the ATMX group, a random effects
repeated measures ANOVA GLM identified regions with MSITInterference fMRI activation
higher at 6 weeks of ATMX treatment than at baseline. A stringent cluster constraint
requiring ≥ 7 contiguous P < .05 voxels (Forman et al., 1995) produced a regional false
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positive probability of P < 1 × 10−4 corrected for multiple comparisons and matched prior
conservative α thresholds.
Secondary analyses compared ATMX fMRI responses to published MPH and placebo data
(Bush et al., 2008). For ATMX versus placebo and MPH analyses, a mask representing all
MSITInterference > MSITControl voxels (P < .05 uncorrected) for all 32 subjects during Scans
1 and 2 restricted analyses to brain areas specifically involved in cognitive task
performance. Within masked voxels, random effects repeated measures ANOVA GLMs
identified brain regions with higher Scan 2 MSITInterference activation in the ATMX group
than the MPH and Placebo groups. An additional step tested for interactions (i.e., regions
had to show both a treatment group (ATMX versus placebo or MPH, respectively) × scan
(Scan 1 baseline versus Scan 2 six weeks) interaction, and a confirmatory two-tailed t-test
had to indicate significantly different Scan 2 activation in ATMX than placebo or MPH,
respectively.
Exploratory analysis compared baseline fMRI responses of the ADHD-CO (N = 21) and
ADHD-NOS (N = 11) groups during the MSIT. A GLM compared the MSITInterference
activation levels at baseline.
3. Results
Primary within subject analysis showed six weeks of ATMX treatment increased activation
of many elements of the CFP cognitive-attention network and other brain regions that MPH
was shown to activate previously (Bush et al., 2008). Specifically, Figure 1 and
Supplemental Table 2 show ATMX increased activation of right DLPFC, inferior parietal
lobule, supplementary motor area, insular cortex, caudate, bilateral cerebellum and fusiform
gyrus. Notably, ATMX did not produce the predicted increase of daMCC activation.
Although the ATMX versus Placebo contrast did not show differences at 6 weeks in a priori
predicted areas of the CFP attention network, seven post hoc clusters showed
ATMX>Placebo at six weeks (Supplemental Table 2). Similarly, ATMX versus MPH
analysis produced no differences in a priori areas, but two post hoc clusters in MCC showed
ATMX>MPH at 6 weeks. No region showed MPH > ATMX group at six weeks.
Baseline GLM comparisons of MSITInterference activation between the ADHD-CO (N = 21)
and ADHD-NOS (N = 11) samples showed no significant differences between the two
groups.
4. Discussion
Six weeks of ATMX treatment was associated with increased activation of the CFP
cognitive-attention network and other brain regions that were previously documented to
activate by MPH treatment (Bush et al., 2008). Notably ATMX did not increase daMCC
activation from baseline. Secondarily, while ATMX did not differentiate versus MPH or
Placebo in a priori predicted areas, post hoc analyses identified ATMX>Placebo at 6 weeks
in multiple MCC clusters and caudate; and ATMX>MPH in two MCC clusters. Neither of
these comparisons showed a significant treatment group × scan interaction. Also, no
differences were found in baseline fMRI activation between ADHD-CO and ADHD-NOS
groups. Together, the data indicate ATMX and MPH have similar but non-identical brain
effects.
To our knowledge this is the first fMRI study of ATMX in ADHD. In fact, there have been
few imaging studies of ATMX, and all have used a single dose in healthy humans or were
done in patients with schizophrenia (Friedman et al., 2008; Chamberlain et al., 2009; Graf et
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al., 2011; Marquand et al., 2011; Hester et al., 2012; Marquand et al., 2012). Our findings
complement and extend such work by showing ATMX effects in adults with ADHD over a
longer, clinically relevant trial period, and using a different task.
The data show that ATMX was associated with increased activation of DLPFC, parietal
cortex, caudate, and cerebellum—brain regions implicated in attention, motor control and
the pathophysiology of ADHD (Bush, 2010). Further, the brain responses to ATMX and
MPH were generally similar, but notable differences existed. ATMX did not activate
daMCC as MPH has been shown to do (Bush et al., 2008). Also, ATMX did not produce
significant activation of other regions activated by MPH, such as premotor cortex and
thalamus. Together, the data indicate that while drug effects may overlap, differences exist
in neurobiological actions.
Together with reported findings of ATMX NET binding changes (Logan et al., 2007), our
data suggest ATMX may exert primary effects by NET receptor binding in the locus
coeruleus, thalamus, midbrain, cingulate cortex and supplementary motor area, along with
possible secondary downstream modulatory effects of DLPFC, parietal cortex and
cerebellum. ATMX may initiate effects by blocking NET and increasing synaptic
availability of norepinephrine, which may boost “downstream” signal-to-noise in fronto-
parietal and cerebellar regions. This could improve attention, filtering of distracting
information, and possibly regulate motor inhibition (thereby reducing hyperactivity and
impulsivity). Differential actions of ATMX and MPH are broadly in line with the
conceptualization of Arnsten (Arnsten, 2009) who concluded ATMX works mainly through
postsynaptic alpha(2A)-receptors on the dendritic spines of PFC pyramidal cells and
partially through D1-dopamine receptor actions. Some of the overlap of ATMX and MPH
effects could be explained by findings that both inhibit NET (Hannestad et al., 2010), though
complex differences between the drugs remain to be characterized.
Limitations include results being only valid for ADHD adults and that, aside from predicted
fronto-parietal and cerebellar activations, other identified regions are post hoc and must be
replicated. Moreover, the sample was small and there was no direct comparison group.
Future work seeking to compare ATMX, MPH and/or placebo should consider a randomized
or crossover design. Specifically, a crossover design would serve to eliminate anatomical
variability between different subject groups in case the ATMX effect is subtle. Also, while
identifying regions by post-medication activation is justifiable and valid for this pilot study,
it does introduce the potential for circularity. Future work building on this pilot study should
consider employing a matched healthy control group whose data will allow independent
definition of regions of interest, avoiding circularity (Kriegeskorte et al., 2010). Finally,
ADHD-NOS and ADHD-CO comparisons in this pilot study are preliminary pending
replication.
In this pilot study, six weeks of treatment with ATMX was associated with increased
activation of brain regions implicated in the pathophysiology of ADHD including DLPFC,
parietal cortex, caudate and cerebellum. Many of these regions had been activated by MPH
in our prior fMRI study, and here the observed differences between ATMX and MPH
activation patterns were minimal. Notably, ATMX did not significantly activate daMCC.
The data indicate that differences in cortical effects of ATMX and MPH may underlie their
differential clinical effects.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Atomoxetine Produces Higher fMRI Activation at 6 Weeks
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Table 1
MSIT Performance Data
Group Scan 1
(Baseline, t = 0)
Interference
Scan 1
(Baseline, t = 0)
Control
Scan 2
(t = 6 weeks)
Interference
Scan 2
(t = 6 weeks)
Control
REACTION TIMES (ms)
ATMX (All) 1026 ± 77 702 ± 104 922 ± 145 634 ± 121
ACCURACY (%)
ATMX (All) 95.6 ± 3.1 95.4 ± 5.8 92.1 ± 9.0 90.0 ± 8.4
Means and standard deviations are presented for RT (ms) and accuracy (% correct). RT and accuracy data were lost/corrupted for two subjects,
both of whom were ATMX treatment responders. Thus the term ‘all’ refers to full remaining group data (N = 9 of 11), divided between ATMX
Responders (N = 5 of 7 responders) and ATMX Failures (N = 4). Repeated measures ANOVAs showed that the ATMX group displayed the
expected interference effects (RTinterference > RTcontrol with significant main effects of condition [F1,8 = 130.2, P < .001]) and scan (F1,8 =
9.5, P < .05), but no scan × condition interaction (P = .12, N.S.) for RT. For accuracy, the ATMX group did not show a significant main effect of
condition [F1,8 = 1.1, P = .32, N.S.]) or scan (F1,8 = 2.9, P = 1.3, N.S.), and did not display a significant scan × condition interaction (P = .53,
N.S.). Separate 3 (Group: ATMX vs. MPH vs. Placebo) by 2 (Condition: MSITinterference vs. MSITcontrol) by 2 (Scan [Scan 1 (baseline, t = 0)
vs. Scan 2 (t = 6 weeks)] repeated measures ANOVAs were performed for RT and accuracy. For RT, there were main effects of group (F2,27 =
11.2, P < .001), scan (F2,27 = 68.3, P < .001) and condition (F2,27 = 503.5, P < .0001), but no scan × group (P = .98), condition × group (P = .53),
nor scan × condition × group (P = .72) interactions for RT. For accuracy, there were main effects of group (F2,27 = 8.3, P < .01) and condition
(F2,27 = 4.7, P < .05), but not of scan (F2,27 = 1.0, P = .33). There were scan × group (F2,27 = 3.7, P < .05) and condition × group (F2,27 = 5.6, P
< .01) interactions, but not a scan × condition × group (F2,27 = 0.1, P = .92, N.S.) interaction.
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Table 2
Brain Regions Showing Higher MSIT Activation After a 6-Weeks Trial of Atomoxetine than at Baseline (time
= 0) in ADHD Adults
Brain Region
x y z
Region Size
(Voxels)
R. DLPFC - Middle Frontal Gyrus (9) 45 22 28 7
L. Supplementary Motor Area (6) −8 −4 58 23
L. Insula −30 2 13 7
L. Substantia nigra −3 −14 −8 25
L. Postcentral Gyrus (1) −51 −23 40 29
L. Inferior Parietal Lobule (40) −36 −33 46 35
L. Caudate Tail −22 −34 15 56
L. Posterior Cingulate Cortex (31) −12 −55 34 9
L. Cerebellum −21 −60 −47 17
R. Cerebellum 4 −54 −29 16
L. Fusiform Gyrus (19) −24 −58 1 13
L. Fusiform Gyrus (19) −36 −64 −2 15
Group-averaged activation locations and extents are shown for brain regions that showed higher fMRI activation in ADHD adults (N = 11) during
MSIT Interference trials after 6 weeks of ATMX. The activation locations shown are the result of a random effects GLM analysis, with a voxel-
wise threshold of P < .05 and to which an additional rigorous 7 contiguous voxel cluster constraint was applied to correct for multiple comparisons
(cluster corrected P < .0001). Stereotactic coordinates are presented for local maxima according to the convention of Talairach and Tournoux
(1988). Coordinates are expressed in millimeter units. The origin (0,0,0) is the anterior commissure at the midsagittal plane, with x > 0
corresponding to right of midsagittal, y > 0 corresponding to anterior, and z > 0 corresponding to superior. Cytoarchitectural areas are indicated in
parentheses after the named structure.
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